Classification of systemic sclerosis. Visions and reality

Rheumatology

Volumn 44, Issue 10, 2005, Pages 1212-1216

  Wollheim, Frank A ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNITY; CAPILLAROSCOPY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; GENETIC HETEROGENEITY; HUMAN; IDIOPATHIC DISEASE; LIFE EXPECTANCY; MEDICAL PRACTICE; PRIORITY JOURNAL; PROGNOSIS; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SKIN DISEASE; SURVIVAL; SYNDROME CREST; SYSTEMIC SCLEROSIS; VIDEORECORDING;

CREST SYNDROME; HUMANS; MICROSCOPIC ANGIOSCOPY; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC;

EID: 26444614639     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh671     Document Type: Review

References (45)

1. Denton CP, Abraham DJ. Transgenic analysis of scleroderma: Understanding key pathogenic events in vivo [Review]. Autoimmun Rev 2004;3:285-93.
2. Reveille JD. Genetic studies in the rheumatic diseases: Present status and implications for the future. J Rheumatol Suppl 2005; 72:10-13.
3. Markiewicz M, Smith EA, Rubinchik S, Dong JY, Trojanowska M, LeRoy EC. The 72-kilodalton IE-1 protein of human cytomegalovirus (HCMV) is a potent inducer of connective tissue growth factor (CTGF) in human dermal fibroblasts. Clin Exp Rheumatol 2004;22(3 Suppl. 33):S31-4.
4. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
5. American Rheumatism Association. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
6. Winterbauer RH. Multiple telangiectasia, Raynaud's phenomenon, sclerodactyly, and subcutaneous calcinosis: A syndrome mimicking hereditary hemorrhagic telangiectasia. Bull Johns Hopkins Hosp 1964;114:361-83.
7. Langaard H. [Dysphagia, Raynaud's disease, calcinosis cutis; a nosological entity as expression of scleroderma.] Ugeskr Laeger 1959;121:210-3.
8. Tuffanelli DL, Winkelmann RK. Diffuse systemic scleroderma. A comparison with acrosclerosis. Ann Intern Med 1962;57:198-203.
9. Barnett AJ. Scleroderma (progressive systemic sclerosis): Progress and course based on a personal series of 118 cases. Med J Aust 1978;2:129-34.
10. Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971;75:369-76.
11. Vancheeswaran R, Magoulas T, Efrat G et al. Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21:1838-44.
12. Åkesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: A comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 1989; 28:281-6.
13. Clements PJ, Lachenbruch PA, Ng SC et al. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990;33:1256-63.
14. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Åkesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 2003; 42:534-40.
15. Tager RE, Tikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans. Rheumatology 1999;38:397-400.
16. Kuwana M, Kaburaki J, Arnett FC et al. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999;42:465-74.
17. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
18. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986;13:911-6.
19. Ferri C, Valentini G, Cozzi F et al. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002;81:139-53.
20. Scussel-Lonzetti L, Joyal F, Raynauld JP et al. Predicting mortality in systemic sclerosis: Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81:154-67.
21. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: Development of a simple model using three disease factors at first visit. Arthritis Rheum 1999;42:2660-5.
22. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998;37:750-5.
23. Wollheim E. Zur Funktion der subpapillären Gefässplexus in der Haut. Klin Wochenschr 1927;6:2134-7.
24. Maricq HR. Wide-field capillary microscopy. Arthritis Rheum 1981;24:1159-65.
25. Nagy Z, Czirjak L. Nailfold digital capillaroscopy in 447 patients with connective tissue disease and Raynaud's disease. J Eur Acad Dermatol Venereol 2004;18:62-8.
26. Wildt M, Hesselstrand R, Scheja A, Akesson A. Capillary density in patients with systemic sclerosis, as determined by microscopy counts and compared with computer-based analysis. Clin Exp Rheumatol 1999;17:219-22.
27. Bukhari M, Hollis S, Moore T, Jayson MI, Herrick AL. Quantitation of microcirculatory abnormalities in patients with primary Raynaud's phenomenon and systemic sclerosis by video capillaroscopy. Rheumatology 2000;39:506-12.
28. Cutolo M, Pizzorni C, Tuccio M et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology 2004;43:719-26.
29. Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by 'wide-field' microscopy. Arthritis Rheum 1973;16:619-28.
30. Maricq HR, Valter I. A working classification of scleroderma spectrum disorders: A proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 2004;22(3 Suppl. 33): S5-13.
31. Bodolay E, Csiki Z, Szekaneez Z et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 2003;21:313-20.
32. Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980;23:617-25.
33. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998;37:15-20.
34. Yang JM, Hildebrandt B, Luderschmidt C, Pollard KM. Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar RNP complex. Arthritis Rheum 2003;48:210-7.
35. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003;48:203-9.
36. Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma. Arthritis Rheum 2004;50:227-32.
37. Moore TL, Lunt M, McManus B, Anderson ME, Herrick AL. Seventeen-point dermal ultrasound scoring system - a reliable measure of skin thickness in patients with systemic sclerosis. Rheumatology 2003;42:1559-63.
38. Reveille JD. Genetic studies in the rheumatic diseases: Present status and implications for the future. J Rheumatol Suppl 2005;72:10-3.
39. Namboodiri AM, Rocca KM, Pandey JP. IgG antibodies to human cytomegalovirus late protein UL94 in patients with systemic sclerosis. Autoimmunity 2004;37:241-4.
40. Pandey JP. Immunoglobulin GM genes and IgG antibodies to cytomegalovirus in patients with systemic sclerosis. Clin Exp Rheumatol 2004;22(3 Suppl. 33):S35-7.
41. Markiewicz M, Smith EA, Rubinchik S, Dong JY, Trojanowska M, LeRoy EC. The 72-kilodalton IE-1 protein of human cytomegalovirus (HCMV) is a potent inducer of connective tissue growth factor (CTGF) in human dermal fibroblasts. Clin Exp Rheumatol 2004;22(3 Suppl. 33):S31-4.
42. Lunardi C, Bason C, Navone R et al. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000;6:1183-6.
43. Vaughan JH, Shaw PX, Nguyen MD, Medsger TA Jr, Wright TM, Metcalf JS. Evidence of activation of 2 herpesviruses, Epstein-Barr virus and cytomegalovirus, in systemic sclerosis and normal skins. J Rheumatol 2000;27:821-3.
44. Neidbart M, Kuchen S, Distler O, Bruhlmamn P, Michel BA, Gay RE, Gay S. Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis. Arthritis Rheum 1999;42:389-92.
45. Haustein UF, Pustowoit B, Krusche U, Herrmann K. Antibodies to retrovirus proteins in scleroderma. Acta Derm Venereol 1993;73:116-8.